There's been an alarming increase of respiratory and gastrointestinal viruses in the United States lately, causing anxiety about a so-called "quad-demic". According to surveillance reports, influenza, COVID-19, RSV and norovirus are at very high levels everywhere. While the surge aligns with patterns typical for this season, several epidemiologists view simultaneous infections of such proportions to pose risks not only to individual healthcare but public health.

The incidence of the quad-demic should vary with seasonal patterns, vaccination rates, and public health interventions. Each virus alone is relatively easy to manage; however, the effect of all together could lead to overburdening of health care facilities and increase risks for those at higher risk. Continuing surveillance, early testing, and proactive prevention measures will play an important role in the control of these infections going forward.

While the term "quad-demic" sounds daunting, it must be taken into perspective. For years, we have had all these viruses together, and we have the capabilities to mitigate some of the risk. Vaccination, proper hygiene and using common sense helps individuals get through the season unscathed. Is the quad-demic a permanent fixture or just another seasonal wave? Let's break this down.

What is the Quad-demic?

Typically, flu, COVID-19, and RSV have been the primary culprits behind seasonal respiratory infections. However, norovirus, a highly contagious stomach bug, has emerged as a fourth significant player, inducing fears of a more severe and widespread viral outbreak. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded nearly 500 norovirus outbreaks between August and December 2023, a substantial rise from the previous year’s numbers.

While the term "quad-demic" may sound ominous, the seriousness and consequences of such infections should be weighed in light of the U.S. healthcare system's experience with managing viral surges since the start of the COVID-19 pandemic.

1. Influenza (Flu)

Flu continues to be one of the most common and alarming seasonal illnesses. In the period spanning from 2023 to 2024, there were approximately 40 million cases of flu, and thousands of hospitalizations along with reported 47 deaths have been reported this season. Flu symptoms include fever, chills, cough, sore throat, muscle pain, and fatigue, with most recovering within a week or two but risky factors for severe illness effects occur in young children, elderly, and people with chronic conditions.

2. Covid-19

Despite its reduction from the first pandemic peak, COVID-19 is still rampant. The CDC estimates that alone between October and December 2023, there were between 2.7 and 5 million cases in the U.S. Hospitalization has increased by cities such as Los Angeles, Chicago, and New York. Symptoms are closely similar to the flu, fever, cough, and fatigue but uniquely presents in some cases as loss of taste and smell.

3. RSV

RSV is the most common cause of lower respiratory infections in infants, older adults, and immunocompromised individuals. While RSV peaked late in 2023 and early 2024, it continues to be a threat because it can lead to bronchiolitis and pneumonia. It is very similar to the common cold, presenting with symptoms such as congestion, runny nose, coughing, and fever, which can make it difficult to differentiate from flu or COVID-19 without testing.

4. Norovirus

Norovirus, also called the "stomach flu," is a highly contagious infection of the gastrointestinal tract, not a respiratory virus. It transmits quickly from contaminated food and water and contact with contaminated surfaces, causing such symptoms as diarrhea, vomiting, nausea, and stomach pain. Cases have shot up, the CDC said Monday, with reports of outbreaks surging compared with last year.

Is There a Challenge In Diagnosis Due to Overlapping Symptoms?

The greatest challenge during the quad-demic is how the four viruses are alike and thus make identification very hard with no testing applied. Most cases present symptoms common to all viruses: fever, tiredness, body pains, and respiratory, which includes coughing and congestions for influenza, COVID-19, and RSV; the other would be norovirus symptoms as nausea and vomiting can appear even in extreme influenza and COVID-19. This overlap increases the risk of misdiagnosis and delayed treatment, hence the need for early testing and proper medical guidance.

Also Read: Is US Preparing For A Quad- demic 2025?

Effective Prevention Strategies That Work

The best defense against these viruses is a combination of vaccines, hygiene, and lifestyle precautions. While lifestyle modifications are highlighted as part of the constant need to eat healthy, ensure daily movement and drinking adequate amount of fluids. There is a sure short two preventive strategies that are effective:

Vaccination

• Flu vaccine: Annual flu shots reduce the severity of infection, allergic flare ups and hospitalizations.
• COVID-19 vaccine: Though COVID-19 cases have declined, vaccination remains critical in preventing severe outcomes.
• RSV vaccine: Available for those aged 60 years and older, especially those with underlying conditions.
• Norovirus vaccine: No vaccine is yet available, but mRNA vaccine research is in progress.

Hygiene and Sanitation

• Washing hands frequently with soap and water for at least 20 seconds, especially after public exposure.
• Disinfect frequently touched surfaces regularly, use sanitiser when outside.
• Avoid close contact with infected people and wear masks.

Do You Need To Wear A Mask All The Time?

While debates on masked wear continue on, experts on mask-wear affirm that this does not only have a historical precedent but works towards reducing airborne viruses spreading within the environments. Hospitals, though, ensure masking in key sections of themselves. Publicized mask-wear remains a discretion, though massing indoors still goes a longer way in cases like peak flu seasons.

If you notice the symptoms of these viruses, then it's best to be confined at home and avoid having face-to-face interaction with others and seek immediate attention from your physician if your condition worsens. Quarantining for some days can decrease the spread of infection.

As we move into the first half of 2025 and beyond, staying informed and proactive is the best strategy for maintaining health and avoiding unnecessary panic. The key takeaway? Stay vigilant, but don’t be alarmed—these viruses are here, but so are the means to fight them.

China has become the world’s first country to approve a monoclonal antibody drug called Libevitug to treat hepatitis D — a severe, chronic liver disease.

The drug, which was rolled out at a Beijing hospital recently, was granted conditional approval by China's National Medical Products Administration in January 2026 following priority review, Science and Technology Daily reported.

Libevitug is a monoclonal antibody developed by a team from Tsinghua University and the Beijing-based biopharmaceutical company Huahui Health.

It works by blocking hepatitis B and D viruses from entering liver cells.

Clinical trials on Libevitug demonstrated significant efficacy in virological response and normalization of liver function, with particularly notable benefits for patients with cirrhosis.

What Is Hepatitis D? What Are The Key Symptoms?

Hepatitis D, or HDV, is different from the others—it can't infect the liver by itself. It only exists in those already infected with hepatitis B, employing the outer shell of the HBV virus to replicate.

When HBV and HDV infect the liver concurrently (a co-infection) or if HDV is contracted later on superimposition of pre-existing HBV (a superinfection), the immune system is twice assaulted. The liver has to cope with more intense inflammation, resulting in more rapid fibrosis progression and a much increased risk of cirrhosis and hepatocellular carcinoma.

In individuals with co-infection, liver injury is more severe, and complications arise years sooner than in HBV mono-infection. There are no specific therapies for HDV currently, and its management relies mostly on the control of hepatitis B.

It is also possible to prevent HBV infection and thereby hepatitis D by vaccination. Antiviral therapy and close follow-up can likewise decrease the chances of serious HDV complications in those already infected with HBV.

Simultaneous infection with HBV and HDV can lead to mild-to-severe hepatitis, with signs and symptoms typically appearing 3–7 weeks after initial infection and include:

• fever,
• fatigue,
• loss of appetite,
• nausea,
• vomiting,
• dark urine,
• pale-colored stools,
• jaundice (yellow eyes)
• fulminant hepatitis.

Also read: Hepatitis On Rise In India: What Is Causing It?

How Does Libevitug Work?

Of the over 254 million chronic hepatitis B carriers worldwide, approximately 5 percent are co-infected with the hepatitis D virus, and patients with co-infection have long lacked effective targeted therapies.

Clinical trials for the drug began in 2018, with an international multi-center study launched in 2023 among patients with chronic co-infection.

The drug previously received "Breakthrough Therapy Designation" from both the Center for Drug Evaluation (CDE) of the China NMPA and the US Food and Drug Administration (FDA).

Also read: Hepatitis A To E: How Each Virus Affects Your Liver?

"Libevitug demonstrates outstanding clinical efficacy and significantly improves liver stiffness, with particularly remarkable efficacy in patients with HBV/HDV-related cirrhosis," stated Professor Niu Junqi, principal investigator of the Libevitug trial from the First Hospital of Jilin University.

"This drug aligns with the core objectives of China's Action Plan for the Prevention and Control of Viral Hepatitis (2025–2030), which aims to improve diagnosis and treatment rates for viral hepatitis and reduce the incidence of liver cancer and mortality," Junqi added.

Junqi noted that Libevitug is expected to effectively lower the risk of disease progression to advanced severe diseases such as liver cancer, drive the diagnosis and treatment of HDV in China, as well as advance the goal of eliminating viral hepatitis as a public health problem by 2030.

Amid the growing burden of Non-Communicable Diseases (NCDs), India’s Union Ayush Ministry has launched yoga protocols that will target vulnerable groups with diabetes, high blood pressure, and asthma.

The “Yoga Protocol for Non-Communicable Diseases (NCDs) and Target Groups” is a significant push towards reshaping the country’s healthcare narrative from treatment to prevention, PTI reported.

NCDs such as diabetes, hypertension, cardiovascular ailments, chronic respiratory conditions, and mental health disorders are increasing significantly in the country. These also account for about 60 percent of all deaths in the country, signaling a clear need to focus on preventing the lifestyle-driven illnesses.

Also Read: IPL 2026: Rohit Sharma's Transformation Impresses Nita Ambani; Fitness Secrets Revealed

Prataprao Jadhav, Union Minister of State (Independent Charge) for Ayush, noted that prevention of these conditions is important for the better health of the nation, and yoga is India’s answer to the rising burden of lifestyle diseases.

“Through these evidence-based protocols, we are empowering every citizen to take charge of their own health and well-being in a simple, accessible, and sustainable manner. By integrating yoga into daily life, we aim to shift the focus from illness to wellness, reducing long-term healthcare pressures,” he said.

“This initiative reflects our commitment to building a healthier nation through holistic, preventive, and people-centric approaches rooted in India’s rich traditional knowledge,” the minister added.

What Are The Protocols?

It is part of the Yoga Mahotsav 2026, launched earlier this month by Union Ayush Minister Prataprao Jadhav, developed by the World Health Organization (WHO).

The protocols are designed as structured, evidence-based modules that integrate Yogic practices into daily life in a simple, accessible, and scalable manner.

The initiative has specific yoga interventions curated for major health conditions such as:

• diabetes — improving metabolic balance and glycemic control;
• hypertension — calming the nervous system and regulating blood pressure;
• bronchial asthma — strengthening respiratory capacity and improving lung function
• emotional well-being — breathing and meditation aimed at reducing stress, anxiety, and depression.

Further, it includes

• playful yoga modules for young children
• mental health-focused routines for adolescents,
• mobility-enhancing practices for the elderly
• specialized guidelines for women and pregnant mothers.

Yoga 365

The Ministry of Ayush has also launched Yoga 365 — a nationwide campaign to make yoga an integral part of citizens' daily lives — that goes beyond the International Day of Yoga (IDY), marked annually on June 21 worldwide.

According to the National Sample Survey (NSS), awareness of traditional systems like yoga stands at 95 percent in rural India and 96 percent in urban India.

The NSS also found that in around 1.1 crore households in rural India and around 1.4 crore households in urban India, at least one household member regularly practices yoga.

The Yoga 365 campaign aims to

• mobilize communities through mission-mode outreach,
• promote behavior change,
• integrate yoga into diverse spaces—from schools and offices to neighborhood groups and digital platforms.

The Morarji Desai National Institute of Yoga, under the Ministry of Ayush, has also signed a Memorandum of Understanding with the wellness platform Habuild to offer free daily online yoga sessions.

The COVID-19 BA.3.2 strain, nicknamed Cicada Variant, is spreading rapidly in the US, raising the possibility of becoming the dominant strain in the country, according to experts.

The US Centers for Disease Control and Prevention (CDC), in its latest report, has raised concerns about BA.3.2 — a highly mutated variant of COVID.

BA.3.2 has already been reported in at least 23 countries, including 25 states in America, as per the report. It has also been detected in 132 wastewater samples from Massachusetts.

Also Read: Bipolar Disorder: How Early Detection Can Help Prevent Serious Complications

The 25 states include California, Connecticut, Florida, Hawaii, Idaho, Illinois, Louisiana, Maine, Michigan, Maryland, Massachusetts, Missouri, New Hampshire, New Jersey, Nevada, New York, Ohio, Pennsylvania, Rhode Island, South Carolina, Texas, Utah, Vermont, Virginia, and Wyoming.

"Cicada can become the dominant strain in the US,” Dr. Robert H. Hopkins Jr., medical director of the National Foundation for Infectious Diseases, told USA TODAY.

While it is not certain, it can also "drive a US summer surge.”

The CDC warned that a new variant "with substantial capacity to evade immunity from previous infections or vaccines could be associated with seasonal increases in COVID-19 activity.”

In the US, COVID-19 is still linked to roughly 300 to 500 deaths per week, according to recent data based on provisional estimates from the CDC.

Brandon Dionne, an associate clinical professor of pharmacy and health systems sciences at Northeastern University, stated that the virus may evolve and increase the possibility of more severe disease.

“It’s something we definitely want to monitor,” Dionne said. “It could, over time, become the dominant strain in the US, but it’s not yet there," he said.

Also read: COVID Variant BA.3.2 Spreads To 23 Countries: Is The Variant Under Monitoring A Cause Of Worry?

What Is The Cicada COVID Variant?

Cicada was first identified in a respiratory sample in South Africa in November 2024.

It is a descendant of the Omicron BA.3 lineage, and is genetically distinct from the previously circulating JN.1 lineages (including LP.8.1 and XFG).

BA.3.2 comprises two major branches, BA.3.2.1 and BA.3.2.2. BA.3.2.2 also has substitutions like: K356T, A575S, R681H, and R1162P.

The World Health Organization (WHO) has designated BA.3.2 as a Variant Under Monitoring (VUM). It means the variant may not be that dangerous yet, but it may have concerning mutations.

The CDC’s latest Morbidity and Mortality Weekly Report explains that Cicada has “70 to 75 substitutions and deletions in the gene sequence of its spike protein”.

Also read: Maternal Vaccination During Pregnancy Can Prevent COVID-related Hospitalization In Babies: Study

Will Current COVID Vaccines Work?

The variant is particularly concerning as it provides no immune protection to people with previous infection or even vaccination.

“The number of mutations from JN.1 viruses makes it less likely that the current vaccines will be highly effective against Cicada, but we need more data to better answer this question,” Dr. Hopkins Jr. said.

However, according to the WHO, current COVID vaccines are expected to continue protecting against severe disease. Moreover, the WHO said BA.3.2 doesn’t seem to be making people sicker so far and hasn’t resulted in increased hospitalizations and deaths.

Common symptoms of Cicada variant include:

• Cough
• Fever or chills
• Sore throat
• Congestion
• Shortness of breath
• Loss of smell or taste
• Fatigue
• Headache.